open access

Vol 6, No 6 (2010)
Review paper
Published online: 2011-02-24
Get Citation

Epidemiology, screening and staging of colorectal cancer

Piotr Potemski
Onkol. Prak. Klin 2010;6(6):283-289.

open access

Vol 6, No 6 (2010)
REVIEW ARTICLES
Published online: 2011-02-24

Abstract

In Poland in 2007, 14 244 new cases of colorectal cancer (C18–C20) were observed — 6352 in women and 7892 in men. Colorectal cancer was the third most common cancer (behind lung and breast cancer) and corresponded with 11.1% of all new cancer cases. Estimated incidence rate in Poland in 2008 was 49.3/100 000 per year in men and 25.7 in women, whereas mortality rate was 29.8 and 15.7, respectively. In European countries colorectal cancer is the most common malignant neoplasm and corresponds with 13.6% of all new cancer cases. Estimated incidence rate in 2008 was 57.1/100 000 per year in men and 35.4 in women, whereas mortality rate was 26.8 and 16.6, respectively. European Society for Medical Oncology (ESMO) recommends faecal occult blood test repeated every 1–2 years as a screening method in men and women aged 50 years and more. It has been shown that such screening reduces mortality from colorectal cancer by 25%. In the newest, seventh edition of Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) colorectal cancer staging classification, inter alia T4 tumours are subdivided into T4a (penetration of the surface of the visceral peritoneum) and T4b (invasion of other organs). There is also a subdivision of N1 and N2 in respect of number of involved lymph nodes into N1a (1 node), N1b (2–3 nodes), N2a (4–6 nodes) and N2b (7 or more nodes). Five-year survival rate of patients with colon cancer diagnosed in Poland between 1995 and 1999 was 38.7% (mean in European countries 54.5%) and with rectal or anal cancer it was 38.9% (mean in European countries 53.2%).


Onkol. Prak. Klin. 2010; 6, 6: 283–289

Abstract

In Poland in 2007, 14 244 new cases of colorectal cancer (C18–C20) were observed — 6352 in women and 7892 in men. Colorectal cancer was the third most common cancer (behind lung and breast cancer) and corresponded with 11.1% of all new cancer cases. Estimated incidence rate in Poland in 2008 was 49.3/100 000 per year in men and 25.7 in women, whereas mortality rate was 29.8 and 15.7, respectively. In European countries colorectal cancer is the most common malignant neoplasm and corresponds with 13.6% of all new cancer cases. Estimated incidence rate in 2008 was 57.1/100 000 per year in men and 35.4 in women, whereas mortality rate was 26.8 and 16.6, respectively. European Society for Medical Oncology (ESMO) recommends faecal occult blood test repeated every 1–2 years as a screening method in men and women aged 50 years and more. It has been shown that such screening reduces mortality from colorectal cancer by 25%. In the newest, seventh edition of Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) colorectal cancer staging classification, inter alia T4 tumours are subdivided into T4a (penetration of the surface of the visceral peritoneum) and T4b (invasion of other organs). There is also a subdivision of N1 and N2 in respect of number of involved lymph nodes into N1a (1 node), N1b (2–3 nodes), N2a (4–6 nodes) and N2b (7 or more nodes). Five-year survival rate of patients with colon cancer diagnosed in Poland between 1995 and 1999 was 38.7% (mean in European countries 54.5%) and with rectal or anal cancer it was 38.9% (mean in European countries 53.2%).


Onkol. Prak. Klin. 2010; 6, 6: 283–289

Get Citation

Keywords

colorectal neoplasms; epidemiology; diagnosis; screening; neoplasm staging; prognosis

About this article
Title

Epidemiology, screening and staging of colorectal cancer

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 6 (2010)

Article type

Review paper

Pages

283-289

Published online

2011-02-24

Bibliographic record

Onkol. Prak. Klin 2010;6(6):283-289.

Keywords

colorectal neoplasms
epidemiology
diagnosis
screening
neoplasm staging
prognosis

Authors

Piotr Potemski

References (15)
  1. www.onkologia.org.pl.
  2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46(4): 765–781.
  3. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12): 2893–2917.
  4. http://seer.cancer.gov..
  5. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005; 16(3): 481–488.
  6. Labianca R, Nordlinger B, Beretta GD, et al. ESMO Guidelines Working Group. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5: v70–v77.
  7. Hewitson P, Glasziou P, Irwig L, et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev. 2007(1): CD001216.
  8. NCCN Clinical Practice Guidelines in Oncology: Colorectal cancer screening. Version 1.2011. www.nccn.org..
  9. Regula J, Rupinski M, Kraszewska E, et al. Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med. 2006; 355(18): 1863–1872.
  10. Lynch HT, de la Chapelle A. Hereditary colorectal cancer . N Engl J Med. 2003; 348: 919–932.
  11. Balmaña J, Castells A, Cervantes A, et al. ESMO Guidelines Working Group. Familial colorectal cancer risk: ESMO Clinical Practice Guidelines. Ann Oncol. 2010; 21 Suppl 5: v78–v81.
  12. AJCC Cancer Staging Handbook. 7 th Edition. Springer-Verlag, Chicago 2010: 173–206.
  13. Sobin L, Gospodarowicz M, Wittekind C. TNM. Klasyfikacja nowotworów złośliwych. Via Medica, Gdańsk 2010: 79–83.
  14. Gatta G, Faivre J, Capocaccia R, et al. Survival of colorectal cancer patients in Europe during the period 1978–1989. European Journal of Cancer. 1998; 34(14): 2176–2183.
  15. Gatta G, Faivre J, Capocaccia R, et al. Survival of colorectal cancer patients in Europe during the period 1978–1989. European Journal of Cancer. 1998; 34(14): 2176–2183.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl